Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

08/04/2020 | 12:02am EST

SAN FRANCISCO and COVINGTON, Ky., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, and CTI Clinical Trial and Consulting Services (CTI), a leading contract research organization, announced enrollment of the first patients in Brazil of a randomized, placebo-controlled Phase 2 proof-of-concept trial of ANG-3777 plus standard of care in patients with acute lung injury associated with COVID-19 pneumonia.

“We’re pleased to enroll the first patients in the trial so soon after initiating the trial,” commented John Neylan, M.D., Angion’s Senior Vice President and Chief Medical Officer. “We worked closely with CTI to commence this study in Brazil, which continues to be tremendously impacted by COVID-19.” 

The Phase 2 trial is a multicenter, prospective, randomized, double-blind, placebo-controlled trial to assess safety and efficacy of ANG-3777 in patients hospitalized with confirmed COVID-19 pneumonia. The primary endpoint of the trial is the proportion of patients alive, without the need for mechanical ventilation and free of the need for renal replacement therapy (on an ongoing basis) at day 28. Angion expects to enroll approximately 100 patients in the trial. Patients will be randomized at a ratio of one-to-one to receive four intravenous doses of 2.0 mg/kg of ANG-3777 plus standard of care versus placebo plus standard of care. This ANG-3777 dosing regimen was previously approved for investigational use in Brazil, allowing for a quicker initiation of this trial for a population in need. If the Phase 2 trial is successful in patients with acute lung injury associated with COVID-19 pneumonia, we intend to submit an investigational new drug application (IND) in the United States

“As COVID-19 cases continue to rise in Brazil, the need for accelerated timelines and additional developmental treatment options increases exponentially,” said Tim Schroeder, Founder and CEO of CTI. "The CTI and Angion teams have worked tirelessly to move this program along as quickly as possible without sacrificing safety or quality, and we look forward to the continued progress of the trial.”

The clinical rationale for this Phase 2 clinical trial of ANG-3777 in patients with acute lung injury associated with COVID-19 pneumonia is rooted in the compelling activity ANG-3777 has shown in several preclinical in vivo models of acute lung injury such as radiation-induced lung injury, chlorine (Cl2)-induced acute lung injury, bleomycin-induced pulmonary edema, TGFβ1-induced mortality and lung fibrosis, lipopolysaccharide (LPS)-induced shock, and lung ischemia-reperfusion injury.
                         
Additional details on the Phase 2 clinical trial can be found at ClinicalTrials.gov (NCT #04459676)

About ANG-3777
ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the c-Met cascade of pathways involved in tissue repair and organ repair. ANG-3777 has a substantially longer half-life than HGF and we believe ANG-3777 has the potential to be a first-in-class therapeutic addressing acute organ injury. The ongoing clinical trials of ANG-3777 include a placebo-controlled Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a Phase 2 proof-of-concept trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery, and a Phase 2 proof-of-concept trial in patients with acute lung injury associated with COVID-19 pneumonia.

About Angion Biomedica Corp.
Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion’s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. ANG-3777 is currently in clinical trials investigating its impact on acute organ injury, including two forms of acute kidney injury and in acute lung injury. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for fibrotic diseases using a precision-medicine approach. For further information, please visit www.angion.com.

About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com 

For Angion 
  
InvestorsMedia
Daniel Ferry
LifeSci Advisors
daniel@lifesciadvisors.com 
617-430-7576
Cherilyn Cecchini, M.D.
LifeSci Communications
ccecchini@lifescicomms.com 
646-876-5196
  
For CTI
Allison Connaughton
CTI Clinical Trial & Consulting
aconnaughton@ctifacts.com 
513-598-9290
 

Primary Logo


© GlobeNewswire 2020
Latest news "Companies"
01/22Automotive Suspension System Lubricants Market to Grow by 8.05 Mn Gal in 2021, BP Plc and Exxon Mobil Corp. Emerge as Key Contributors to Growth | Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast | Technavio
BU
01/22TOSHIBA : regains Tokyo exchange's top category amid calls for better governance
RE
01/22TYSON FOODS : ROSEN, NATIONAL TRIAL LAWYERS, Announces Investigation of Securities Claims Against Tyson Foods, Inc. - TSN
PR
01/22Crystalline silicon solar PV modules Market to grow by $ 46.90 in 2021, Canadian Solar Inc. and Ja Solar Holdings Co. Ltd. emerge as Key Contributors to growth| Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast|Technavio
BU
01/22TATA MOTORS : Press Release – Increase in passenger vehicle prices
PU
01/22AIRBUS : Testing the future ...
PU
01/22Colchicine reduces the risk of COVID-19-related complications
GL
01/22Jericho Expands Energy Portfolio with Agreement for the Acquisition of Hydrogen Technology
GL
01/22AMYRIS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL : Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amyris, Inc. - AMRS
BU
01/22SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL : KSF REMINDS PEN, QS, SWI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
GL
Latest news "Companies"